Ticker Symbol: ENLV
Enlivex Therapeutics Ltd
$8.17 - 17-09-2024 4 p.m. ET
Exchange: NASDAQ
Country:
Israel
Currency:
USD
Asset
Type: Common Stock
CIK:0001596812
Company Profile
Enlivex is a clinical stage immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
Website: www.enlivex.com
CEO: Dror Mevorach
Tags:
- Biotechnology
- Medical Specialties
- Health Technology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $1.48
Change:
-$0.06
(
-4.51%)
Days Range: $1.45 - $1.56
Beta: 0.86
52wk. High: $4.92
52wk. Low: $1.31
Ytd. Change -65.14%
50 Day Moving Average: $1.67
200 Day Moving Average: $2.42
Shares Outstanding: 18566262
Valuation
Market Cap: 2.7B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A